- cafead   Sep 16, 2024 at 10:12: AM
via Johnson & Johnson is planning a phase 3 program for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encouraging results at ESMO.
article source
article source